義翹神州(301047.SZ)：上半年淨利同比下降56.58%
格隆匯8月11日丨義翹神州(301047.SZ)披露2022年半年度報吿，報吿期內，公司實現營業收入2.99億元，同比下降52.84%。其中新冠病毒相關業務收入1.08億元，同比下降76.33%，非新冠病毒相關業務收入1.91億元，同比增長7.88%；歸屬於上市公司股東的淨利潤1.92億元，同比下降56.58%；基本每股收益1.9493元。
2022年上半年，公司新冠病毒相關業務實現收入1.08億元，佔比36.20%，較上年同期下降，但仍處於較高水平，主要系公司持續關注新冠病毒變異情況，利用病毒領域相關生物試劑的豐富研發經驗，根據市場需求不斷推出相關產品，產品研發速度和品種覆蓋度始終名列前茅，保持了新冠病毒相關生物試劑的主流供應商地位。同時，為增強企業長期競爭力，2022年上半年，公司不斷加大非新冠業務的研發投入。
在公司主營業務重組蛋白領域，成功建立全長多次跨膜蛋白生產技術平台，產品完成開發上線，很好的補充了公司膜蛋白產品的空白；在原有細胞因子產線基礎上，進行產品質量優化升級，提高純度、活性，並陸續推出了高質量GMP級別的細胞因子產品，滿足工業細胞治療客户的需求；另外，在工具酶、藥物靶點蛋白、診斷原料級蛋白方面也不斷取得新突破，一批新產品和優化升級產品預計將在下半年陸續上市銷售。
在抗體業務領域，公司不斷拓展技術平台，引進建設了光導單細胞技術，並充分發揮其快速高通量的技術優勢，第一時間開發出了猴痘病毒抗體，並開始承接工業客户抗體服務項目。另外，2022年上半年，公司不斷拓展技術服務業務領域，在保持既往主營蛋白、抗體表達服務業務的同時，以抗體開發、病毒清除驗證、細胞庫檢測業務為代表的技術服務成功率和客户滿意度持續提升，業務持續快速增長，簽約訂單金額增長率為69.66%，已交付CRO服務實現收入4646.81萬元，同比增長22.24%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
